India Patent Office Dismisses Compulsory License Application of Lee Pharma - 21.01.2016

Indian Patent Office has dismissed application of Lee Pharma for a compulsory licence to make a copy of AstraZeneca's antidiabetes drug saxagliptin, which is branded Onglyza.

Tags : Indian Patent Office Lee Pharma

Share :